Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Obstetrician–gynecologists’ practices and attitudes on substance use screening during pregnancy

Abstract

Objective

To describe obstetrician–gynecologists’ practices and attitudes related to substance use screening in pregnant patients.

Study design

A 2017 cross-sectional survey assessed US obstetrician–gynecologists’ (n = 462; response rate = 34%) practices (substance use screening frequency and methods) and attitudes (practice priority of screening, confidence in treating, and responsibility statements). Chi-squared tests and adjusted modified Poisson regression were used to estimate associations between practices and attitudes.

Results

Of 353 respondents with screening information, 79% frequently screen for substance use and 11% used a validated instrument. Confidence was the highest for treating pregnant patients using tobacco (81%). Respondents whose practices make it a high priority to screen for all substances were 1.2 times as likely to frequently screen as their counterparts (95% CI: 1.1–1.3).

Conclusions

Four out of five obstetricians–gynecologists reported a high frequency of substance use screening in pregnant patients. Findings highlight the importance of increasing priority of substance use screening by obstetrician–gynecologists.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Center for Behavioral Health Statistics and Quality. 2016 National survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2017.

    Google Scholar 

  2. Castles A, Adams EK, Melvin CL, Kelsch C, Boulton ML. Effects of smoking during pregnancy. Five meta-analyses. Am J Prev Med. 1999;16:208–15.

    Article  CAS  Google Scholar 

  3. Dietz PM, England LJ, Shapiro-Mendoza CK, Tong VT, Farr SL, Callaghan WM. Infant morbidity and mortality attributable to prenatal smoking in the U.S. Am J Prev Med. 2010;39:45–52.

    Article  Google Scholar 

  4. U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Srervices, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

    Google Scholar 

  5. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet. 1973;302:999–1001.

    Article  CAS  Google Scholar 

  6. Welch-Carre E. The neurodevelopmental consequences of prenatal alcohol exposure. Adv Neonatal Care. 2005;5:217–29.

    Article  Google Scholar 

  7. Honein MA, Rasmussen SA, Reefhuis J, Romitti PA, Lammer EJ, Sun L, et al. Maternal smoking and environmental tobacco smoke exposure and the risk of orofacial clefts. Epidemiology. 2007;18:226–33.

  8. Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of neonatal abstinence syndrome—28 States, 1999–2013. MMWR Morbidity and mortality weekly report. 2016;65:799–802.

  9. El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the generation R study. J Am Acad Child Adolesc Psychiatry. 2009;48:1173–81.

    Article  Google Scholar 

  10. National Academies of Sciences, Engineering, and Medicine. Prenatal, perinatal, and neonatal exposure to cannabis. In The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. 2017:245–265. Washington D.C.: National Academies Press.

  11. Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6:e009986.

    Article  CAS  Google Scholar 

  12. American College of Obstetricians and Gynecologists. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130:e81–e94.

    Article  Google Scholar 

  13. Davis AM, Wambach KA, Nelson EL, Odar C, Lillis T, McKinley A, et al. Health behavior change in pregnant women: a two-phase study. Telemed J e-Health. 2014;20:1165–9.

    Article  Google Scholar 

  14. Crozier SR, Robinson SM, Borland SE, Godfrey KM, Cooper C, Inskip HM, et al. Do women change their health behaviours in pregnancy? Findings from the Southampton Women’s Survey. Paediatr Perinat Epidemiol. 2009;23:446–53.

    Article  Google Scholar 

  15. U.S. Preventative Services Task Force. Final recommendation statement: tobacco smoking cessation in adults, including pregnant women: behavioral and pharmacotherapy interventions. 2015. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1.

  16. U.S. Preventative Services Task Force. Final recommendation statement: unhealthy alcohol use in adolescents and adults: screening and behavioral counseling interventions. 2018. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions.

  17. U.S. Preventative Services Task Force. Final recommendation statement: drug use, illicit: screening. 2014. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/drug-use-illicit-screening.

  18. U.S. Preventative Services Task Force. Final research plan: drug use in adolescents and adults, including pregnant women: screening. 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/final-research-plan/drug-use-in-adolescents-and-adults-including-pregnant-women-screening

  19. American College of Obstetricians and Gynecologists. Committee opinion No. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2015;125:1529–37.

    Article  Google Scholar 

  20. American College of Obstetricians and Gynecologists. Committee opinion no. 496: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. Obstet Gynecol. 2011;118:383–8.

    Article  Google Scholar 

  21. Committee on Underserved W. Committee on Obstetric P. Committee Opinion No. 721: smoking cessation during pregnancy. Obstet Gynecol. 2017;130:e200–e4.

    Article  Google Scholar 

  22. Diekman ST, Floyd RL, Decoufle P, Schulkin J, Ebrahim SH, Sokol RJ. A survey of obstetrician-gynecologists on their patients’ alcohol use during pregnancy. Obstet Gynecol. 2000;95:756–63.

    CAS  PubMed  Google Scholar 

  23. Anderson B, Parra Dang E, Floyd R, Sokol R, Mahoney J, Schulkin J. Knowledge, opinions, and practice patterns of obstetrician-gynecologists regarding their patients’ use of alcohol. J Addict Med. 2010;4:114–21.

  24. Chang JC, Holland CL, Tarr JA, Rubio D, Rodriguez KL, Kraemer KL, et al. Perinatal illicit drug and marijuana use. Am J Health Promot. 2017;31:35–42.

    Article  Google Scholar 

  25. Floyd RL, Belodoff B, Sidhu J, Schulkin J, Ebrahim SH, Sokol RJ. A survey of obstetrician-gynecologists on their patients’ use of tobacco and other drugs during pregnancy. Prenat Neonatal Med. 2001;6:201–7.

    Google Scholar 

  26. Oser C, Biebel E, Harris M, Klein E, Leukefeld C. Gender differences in provider’s use of a standardized screening tool for prenatal substance use. J Addict Med. 2011;5:36–42.

    Article  Google Scholar 

  27. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008;103:1429–40.

    Article  Google Scholar 

  28. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128:4–10.

    Article  CAS  Google Scholar 

  29. American College of Obstetricians and Gynecologists. Collaborative Ambulatory Research Network CARN. 2018. https://www.acog.org/About-ACOG/ACOG-Departments/Research/Collaborative-Ambulatory-Research-Network--CARN-2.

  30. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.

    Article  Google Scholar 

  31. Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215:539–47.

    Article  Google Scholar 

  32. Hadland SE, Levy S. Objective testing: urine and other drug tests. Child Adolesc Psychiatr Clin N Am. 2016;25:549–65.

    Article  Google Scholar 

  33. Ondersma SJ, Chang G, Blake-Lamb T, Gilstad-Hayden K, Orav J, Beatty JR, et al. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019;114:1683–93.

    Article  Google Scholar 

  34. Ko JY, Tong VT, Haight SC, Terplan M, Snead C, Schulkin J. Obstetrician-Gynecologists’ practice patterns related to opioid use during pregnancy and postpartum—United States, 2017. J Perinatol. 2019. [Epub ahead of print].

  35. Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210:302–10.

    Article  Google Scholar 

  36. Terplan M, Longinaker N, Appel L. Women-centered drug treatment services and need in the United States, 2002–2009. Am J Public Health. 2015;105:e50–4.

    Article  Google Scholar 

  37. Ziegenfuss JY, Shah ND, Fan J, Houten HK, Deming JR, Smith SA, et al. Patient characteristics of provider survey respondents: no evidence of nonresponse bias. Eval Health Prof. 2012;35:507–16.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank the respondents of the survey for their time and participation.

Funding

This work was funded by a contract to the American College of Obstetricians and Gynecologists (ACOG) by the Centers for Disease Control and Prevention (CDC; #200-2015-M-63715). Authors LS, CS, and JS were in part supported by UA6MC19010 and UA6MC31609 from the Maternal Child Health Bureau of the Health Resources and Services Administration (HRSA).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jean Y. Ko.

Ethics declarations

Conflict of interest

The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the U.S. Public Health Service, the Centers for Disease Control and Prevention, HRSA, or the authors’ affiliated institutions.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ko, J.Y., Tong, V.T., Haight, S.C. et al. Obstetrician–gynecologists’ practices and attitudes on substance use screening during pregnancy. J Perinatol 40, 422–432 (2020). https://doi.org/10.1038/s41372-019-0542-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-019-0542-3

This article is cited by

Search

Quick links